Danaher to Acquire Masimo Corporation for $9.9 Billion, Expanding Diagnostics Portfolio
Summary
Danaher Corporation announced a definitive agreement to acquire Masimo Corporation for approximately $9.9 billion, significantly expanding its diagnostics capabilities with advanced patient monitoring solutions.
Key Events
-
Major Acquisition Announced
Danaher Corporation will acquire Masimo Corporation for $180.00 per share in cash, totaling approximately $9.9 billion, including assumed indebtedness.
-
Strategic Expansion in Diagnostics
The acquisition integrates Masimo's leading pulse oximetry and patient monitoring solutions into Danaher's Diagnostics segment, strengthening its acute care offerings.
-
Expected Financial Accretion and Synergies
The transaction is anticipated to be accretive to adjusted diluted net earnings per common share and is expected to generate over $125 million in annual cost synergies and over $50 million in annual revenue synergies by the fifth full year.
-
Funding and Closing Timeline
Danaher plans to fund the acquisition using cash on hand and debt financing, with the transaction expected to close in the second half of 2026, subject to regulatory and shareholder approvals.
Analysis
Danaher Corporation's acquisition of Masimo Corporation for approximately $9.9 billion represents a significant strategic move to bolster its diagnostics segment. Masimo's leadership in pulse oximetry and patient monitoring solutions is expected to enhance Danaher's offerings, particularly in acute care settings. The transaction is projected to be accretive to Danaher's adjusted diluted net earnings per common share, with substantial cost and revenue synergies anticipated over the next five years. This acquisition is a major growth initiative, leveraging Danaher's operational expertise to expand Masimo's market reach and accelerate core revenue growth within the Diagnostics segment.
At the time of this filing, DHR was trading at $200.30 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $150.2B. The 52-week trading range was $171.00 to $242.80. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.